-
公开(公告)号：WO2022254200A1
公开(公告)日：2022-12-08
申请号：PCT/GB2022/051383
申请日：2022-05-31
IPC分类号： G01N33/569 , G01N33/68 , G01N33/50 , G01N2333/70539 , G01N33/5047 , G01N33/56977 , G01N33/6878
摘要： The invention relates to methods of identifying a peptide which is capable of forming an HLA-E:peptide complex and being recognised by a T-cell and or B-cell, and methods of improving the stability of the HLA-E:peptide complex. Further, the invention relates to methods of identifying one or more T-cell or B-cell which recognises an HLA-E:peptide complex.
-
公开(公告)号：WO2021092555A2
公开(公告)日：2021-05-14
申请号：PCT/US2020/059667
申请日：2020-11-09
申请人： KIYATEC, INC.
发明人： APPLETON, Kate , DESROCHERS, Tessa
IPC分类号： G01N33/50 , G01N33/574 , C12M1/00 , C12M1/42 , C12N5/078 , C12N5/071 , C12M35/08 , C12N2503/04 , C12N5/0636 , C12N5/0693 , C12N5/0697 , G01N2800/52 , G01N33/5011 , G01N33/502 , G01N33/5047 , G01N33/505 , G01N33/57484
摘要： The present application contemplates methods of screening therapeutic agents for treating cancer comprising co-culturing immune cells and tumor cells isolated from a subject under conditions that allow the immune cells and the tumor cells to form a cancer spheroid. The cancer spheroid may then be exposed to at least one therapeutic agent, and the responsiveness of the tumor cells in the spheroid to the therapeutic agent may be measured.
-
3.发明申请
公开(公告)号：WO2022204564A2
公开(公告)日：2022-09-29
申请号：PCT/US2022/022030
申请日：2022-03-25
IPC分类号： C12N5/0783 , A61K35/17 , G01N33/50 , A61K2039/5158 , A61K2039/545 , A61K2039/55533 , A61K38/2013 , A61K39/0011 , C12N2501/2302 , C12N2501/515 , C12N2502/1114 , C12N2502/1157 , C12N2502/30 , C12N2503/00 , C12N5/0638 , G01N2333/57 , G01N2500/10 , G01N33/5008 , G01N33/5047 , G01N33/505 , G01N33/6866
摘要： The present invention provides novel processes, compositions, and methods for analyzing or assaying the potency and/or functionality of tumor infiltrating lymphocyte (TIL) products for use in therapy, including human cancer therapy, and analyzing or assaying the potency and/or functionality of other polyclonal products, such as marrow infiltrating lymphocyte (MIL) and peripheral blood lymphocyte (PBL) products. Compositions, methods, and kits for preparing and treating cancer using TIL, MIL, and PBL products are also provided.
-
公开(公告)号：WO2022002873A1
公开(公告)日：2022-01-06
申请号：PCT/EP2021/067738
申请日：2021-06-28
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP) , SORBONNE UNIVERSITÉ , UNIVERSITÉ DE PARIS
发明人： PAGES, Franck , GALON, Jérôme , ZEITOUN, Guy , KIRILOVSKY, Amos
IPC分类号： G01N33/50 , G01N33/574 , G01N33/68 , G01N2800/54 , G01N33/5047
摘要： The inventors assessed in locally advanced rectal cancer whether a diagnostic biopsy-adapted Immunoscore (ISg) could predict response to neoadjuvant treatment (nT) and better define patients eligible to an organ preservation strategy ("Watch-and-Wait"). The inventors showed that ISB was an independent parameter, more informative than pre- (P
-
公开(公告)号：WO2023014933A2
公开(公告)日：2023-02-09
申请号：PCT/US2022/039507
申请日：2022-08-05
申请人： IMMUNIS.AI, INC. , KASSIS, Amin , ERICKSON, Geoffrey , WOJNO, Kirk , VAN NESTE, Leander , HENAO, Ricardo , STYLLI, Harry
发明人： KASSIS, Amin , ERICKSON, Geoffrey , WOJNO, Kirk , VAN NESTE, Leander , HENAO, Ricardo , STYLLI, Harry
IPC分类号： C12Q1/68 , C12Q1/6886 , C07K1/13 , C12Q2600/118 , C12Q2600/136 , C12Q2600/158 , G01N2800/52 , G01N2800/56 , G01N33/5047 , G01N33/56972 , G01N33/57434
摘要： The present disclosure relates to compositions and methods for assessing prostate cancer (e.g., identification of the aggressiveness or indolence of prostate cancer) in a subject. The compositions and methods include obtaining subject specific information (e.g., age, digital rectal exam (DRE) data, prostate volume, prostate density, total prostate-specific antigen (PSA)) and obtaining a biological sample from a subject and determining a measurement for a panel of biomarkers in the biological sample. Compositions and methods of the disclosure find use in both clinical and research settings, for example, within the fields of biology, immunology, medicine, and oncology.
-
公开(公告)号：WO2021198511A1
公开(公告)日：2021-10-07
申请号：PCT/EP2021/058799
申请日：2021-04-02
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITE COTE D'AZUR , CENTRE HOSPITALIER UNIVERSITAIRE DE NICE , HOPITAL DE CANNES
发明人： BOYER, Laurent , AUBERGER, Patrick , IVANOV, Stoyan , COURJON, Johan , POMARES, Christelle , GIORDANENGO, Valérie , VISVIKIS, Orane , LOUBATIER, Céline , VITALE, Sébastien , DUFIES, Océnane , TORRE, Cédric , DOYE, Anne , MUNRO, Patrick , LOTTE, Romain , JACQUEL, Arnaud , ROBERT, Alex
IPC分类号： A61K31/00 , A61K31/18 , A61K31/4184 , A61K31/64 , A61K31/713 , A61K45/06 , A61K31/4706 , A61P31/14 , G01N33/50 , G01N33/5047
摘要： Inventors collect and analyze the blood of patients to determine their cytokine profile in the serum and the profile/activation status of circulating leukocytes by flow cytometry and measure inflammasomes activation using the FAM-FLICA probe that labels activated caspase-1 (that processes pro-IL-1β in mature IL-1β). Moreover, inventors describes that a use of a specific NLRP3 inhibitor (MCC950) allows them to determine that the activation observed in the blood samples is NLRP3 dependent. Accordingly, the invention relates to NLRP3 inhibitors for use in the treatment of SARS-CoV-2 infection and SARS-CoV-2 related disorders in a subject in need thereof.
-
公开(公告)号：WO2022020569A1
公开(公告)日：2022-01-27
申请号：PCT/US2021/042741
申请日：2021-07-22
IPC分类号： C07K1/22 , A61K35/16 , C07K1/16 , A61P37/00 , A61K38/21 , A61K38/212 , A61K38/215 , C12Q1/6883 , C12Q1/70 , C12Q2600/106 , C12Q2600/156 , G01N2800/24 , G01N2800/52 , G01N33/5047 , G01N33/564 , G01N33/6866
摘要： The present invention provides methods, assays and kits for assessment of patients positive for SARS-CoV-2 infection and methods of diagnosis and treatment of COVID-19 disease and for assessment and evaluation of individuals prior to vaccination with live attenuated virus vaccines, particularly including yellow fever vaccines and COVID-19 vaccines, to assess risk for vaccine- associated disease and adverse events, and for evaluation, treatment and management of patients who develop vaccine-associated disease. The invention provides methods and assays for identification and characterization of inborn errors of type I interferon immunity and also auto-antibodies against Type I IFNs that are associated with severe COVID-19 disease or that are correlated and linked with vaccine- associated disease. The invention further provides methods of diagnosing and determining altered response to or susceptibility to SARS-CoV-2 infection or to live attenuated virus vaccines and for applicable and suitable treatment of COVID-19 disease or vaccine-associated disease.
-
8.发明申请
公开(公告)号：WO2021257623A1
公开(公告)日：2021-12-23
申请号：PCT/US2021/037509
申请日：2021-06-15
发明人： SPRANGER, Stefani , DUONG, Ellen
IPC分类号： C12Q1/6886 , C12Q1/6869 , C12Q2600/112 , C12Q2600/118 , C12Q2600/158 , G01N15/14 , G01N33/5047 , G01N33/57492 , G01N33/6893
摘要： Provided herein are compositions and methods of use relating to a novel class of dendritic cells, referred to herein as ISG+ DC, having anti-tumor activity.
-
9.发明申请
公开(公告)号：WO2021122185A1
公开(公告)日：2021-06-24
申请号：PCT/EP2020/085175
申请日：2020-12-09
发明人： A, A , BRIEDEN, Jennifer , PANKRATZ, Jennifer , EVARISTO, Cesar , NÖLLE, Volker , WIECZOREK, Marek
IPC分类号： G01N33/50 , G01N33/533 , G01N33/5047 , G01N33/505
摘要： The invention is directed to a Conjugate for labelling a target moiety on a cell, characterized by general formula (II): Xo - P - Ym, with Y : MHC-complex targeting TCR molecules, P : enzymatically degradable spacer, X : detection moiety, o : integer between 5 and 25, m : integer between 2 and 1000, wherein X and P; P and Y are covalently bound to each other and Y is bound to P via the C-terminus.
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.01 秒)
